Sign in
Create a Profile
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Diseases and Conditions Researched
Hepatitis C
What is the purpose of this trial?
The purpose of this study is to determine if combination therapy with Pegylated Interferon Lambda (BMS-914143) plus Ribavirin (RBV) with a single direct antiviral agent (BMS-790052 or BMS-650032) for 24 weeks is effective and safe for treatment of Chronic Hepatitis C (CHC) compared to current standard therapy with Pegylated Interferon Alpha-2a plus RBV for 48 weeks.
Participation Guidelines
Gender: Both
Click here for detailed participation information for this trial.
| Sponsor: | Bristol-Myers Squibb |
|---|---|
| Dates: | March 4, 2011 |
| Last Updated: | March 28, 2013 |
| Study HIC#: | 1104008336 |
| Clinicaltrials.gov ID: | NCT01309932 |
How will my information be used?
For more information about this trial, contact:
Robert Bruce, Site 042
203-737-6133
Principal Investigator
Robert Douglas Bruce
Internal Medicine
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.
